TY - JOUR T1 - Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma JF - In Vivo JO - In Vivo SP - 2095 LP - 2102 DO - 10.21873/invivo.11709 VL - 33 IS - 6 AU - HIROYUKI TSUCHIE AU - MAKOTO EMORI AU - NAOHISA MIYAKOSHI AU - HIROYUKI NAGASAWA AU - KYOJI OKADA AU - HIROSHI NANJYO AU - YASUTAKA MURAHASHI AU - EMI MIZUSHIMA AU - JUNYA SHIMIZU AU - TOSHIHIKO YAMASHITA AU - YOICHI SHIMADA Y1 - 2019/11/01 UR - http://iv.iiarjournals.org/content/33/6/2095.abstract N2 - Background/Aim: Abnormal expression of CD44 may promote cancer invasion. However, a limited number of studies have investigated the expression of CD44 in soft tissue sarcoma such as myxofibrosarcoma. We evaluated the relationship between expression of the standard form of CD44 (CD44s) and the clinical course of myxofibrosarcoma. Materials and Methods: Forty-four myxofibrosarcoma patients were retrospectively enrolled. Patient information including the proportion of CD44s-positive cells was collected, and multivariate analyses were conducted to determine the relationship between CD44s expression and clinicopathological factors. Results: Although CD44s did not affect prognosis, multivariate analysis indicated that high expression of CD44s predicted poor event-free survival (p=0.004) and local recurrence (p=0.049). CD44s expression was not associated with the occurrence of distant metastasis but was significantly higher in those with lung metastasis (p=0.044). Conclusion: Increased expression of CD44s predicted poor event-free survival and local recurrence and was observed in myxofibrosarcoma patients with lung metastasis. ER -